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RRM1 is the regulatory subunit of ribonucleotide reductase. It is cru-
cial for DNA synthesis and damage repair. In addition, high levels of 
RRM1 are associated with G2 cell cycle arrest and increased apoptosis 
in vitro. To assess its prognostic utility on lung cancer outcome in 
patients with complete surgical resection of NSCLC, we analyzed its 
level of expression by real-time quantitative RTPCR in prospectively 
collected fresh-frozen tumor specimens and independently in formalin-
ﬁxed and parafﬁn-embedded (FFPE) tumor specimens by quantitative 
in situ ﬂuorescence immunohistochemistry (AQUA). We found that 
RRM1 expression was directly correlated with survival; i.e., high levels 
of expression were prognostic of long survival. mRNA and protein 
expression levels of RRM1 were modestly but signiﬁcantly corre-
lated (JCO 22:1878, 2004; NEJM 356:800, 2007). Prior retrospective 
studies had suggested that patients with advanced stage NSCLC and 
high tumoral RRM1 levels that received gemcitabine-based double 
agent chemotherapy did worse than those with low RRM1 levels. This 
paradox has been explored through molecular biological studies in 
recent years. The results of these studies, which have been conducted 
in NSCLC (Cancer Res 64:3761, 2004; JCO 24:4731, 2006), colorectal 
cancer (Cancer Res 65:9510, 2005), and pancreatic cancer (Int J Cancer 
120:1355, 2007) by independent laboratories around the world have un-
equivocally demonstrated that RRM1 is the dominant molecular deter-
minant of gemcitabine efﬁcacy in vitro, in experimental animals, and in 
patients. Thus RRM1 expression in lung cancer patients is a prognostic 
marker; i.e., high levels are associated with good outcome independent 
of therapy; and a predictive marker; i.e., high levels are associated with 
resistance to therapy that is gemcitabine-based. Prospective multi-in-
stitutional clinical trials have been initiated with the goal to utilize this 
knowledge for therapeutic decision making.
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Unlike some tumor types, the majority of the common solid tumors ap-
pear not to be driven by single dominant targetable pathways. Instead, 
diseases such as lung cancer are likely to be much more complex and 
heterogeneous, with many distinct and overlapping subsets of tumors 
within the class, each of which will demand an in depth analysis to 
deﬁne the optimal therapeutic approach. These groups are starting to be 
deﬁned by multiple technologies, and the simplest example is the small 
subset of patients with tumors expressing mutant EGFR, who achieve 
substantial clinical beneﬁt from minimally toxic targeted therapy. Even 
for this small subset of patients with mutant epidermal growth factor 
receptors (EGFR), multiple resistance mechanisms have emerged re-
quiring different salvage strategies. There also appears to be a group of 
patients without EGFR mutations who experience clinically signiﬁcant 
